Eli Lilly Just Handed Insilico $2.75 Billion to Let AI Pick Its Next Pills
Eli Lilly signed a research and licensing deal worth up to $2.75 billion with Insilico Medicine on March 30, 2026, handing the AI-native biotech's generative drug-design platform a shot at filling Lilly's pipeline with molecules no human chemist screened.